newsfilter
← Latest News
Business Wire·

Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits

EW

TRISCEND II randomized trial data presented at ACC show lower mortality with EVOQUE system, when accounting for patient crossover Edwards Lifesciences (NYSE:EW) today announced new data on the EVOQUE transcatheter